Elza C. de Bruin

Capivasertib in Hormone Receptor–Positive Advanced Breast Cancer

Nicholas C. Turner, Mafalda Oliveira, Sacha J. Howell et al. · New England Journal of Medicine · 2023 · 600 citations · Full text

Early ctDNA dynamics as a surrogate for progression-free survival in advanced breast cancer in the BEECH trial

Sarah Hrebien, Valentina Citi, Isaac García-Murillas et al. · Annals of Oncology · 2019 · 151 citations · Full text

Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial

Sacha J. Howell, Angela Casbard, Margherita Carucci et al. · The Lancet Oncology · 2022 · 136 citations · Full text

BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population

Nicholas C. Turner, Ashley E. Alarcon-Rozas, Anne Armstrong et al. · Annals of Oncology · 2019 · 83 citations · Full text

Clinical impact of HLA class I expression in rectal cancer

Frank M. Speetjens, Elza C. de Bruin, Hans Morreau et al. · Cancer Immunology Immunotherapy · 2007 · 53 citations · Full text